You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR NALTREXONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for naltrexone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000195 ↗ Neurobiology of Opioid Dependence: 4 - 4 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 1993-01-01 The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.
NCT00000195 ↗ Neurobiology of Opioid Dependence: 4 - 4 Withdrawn Yale University Phase 2 1993-01-01 The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.
NCT00000196 ↗ Neurobiology of Opioid Dependence: 5 - 5 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 1993-01-01 The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.
NCT00000196 ↗ Neurobiology of Opioid Dependence: 5 - 5 Withdrawn Yale University Phase 2 1993-01-01 The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.
NCT00000230 ↗ Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-01-01 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.
NCT00000230 ↗ Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 Completed University of Vermont Phase 2 1995-01-01 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.
NCT00000231 ↗ Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13 Completed University of Vermont Phase 2 1992-02-01 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for naltrexone

Condition Name

Condition Name for naltrexone
Intervention Trials
Alcoholism 55
Alcohol Dependence 50
Obesity 28
Opioid-Related Disorders 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for naltrexone
Intervention Trials
Alcoholism 124
Opioid-Related Disorders 97
Disease 50
Substance-Related Disorders 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for naltrexone

Trials by Country

Trials by Country for naltrexone
Location Trials
United States 816
Canada 15
Germany 13
China 12
Russian Federation 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for naltrexone
Location Trials
New York 69
Connecticut 58
California 54
Pennsylvania 53
Texas 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for naltrexone

Clinical Trial Phase

Clinical Trial Phase for naltrexone
Clinical Trial Phase Trials
Phase 4 104
Phase 3 62
Phase 2/Phase 3 36
[disabled in preview] 257
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for naltrexone
Clinical Trial Phase Trials
Completed 303
Recruiting 58
Not yet recruiting 47
[disabled in preview] 61
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for naltrexone

Sponsor Name

Sponsor Name for naltrexone
Sponsor Trials
National Institute on Drug Abuse (NIDA) 96
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 61
Yale University 39
[disabled in preview] 98
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for naltrexone
Sponsor Trials
Other 523
NIH 180
Industry 133
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.